| Similar disease activity responses were observed between patients with rheumatoid arthritis who continued treatment with CT-P10, a rituximab biosimilar, and those who switched from innovator rituximab to CT-P10. |
| Switching from innovator rituximab to CT-P10 was not associated with any safety issues. |
| Long-term treatment with CT-P10 was efficacious and well-tolerated. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.